Overview

This independent medical education (IME) series has been created for English, German and Spanish speaking cardiologists and is designed to showcase the latest updates emerging from the data in novel oral anticoagulants in non-valvular atrial fibrillation patients undergoing PCI.

It will consider the latest recommendations on bleeding risks and the impact this has on the optimum duration of therapy with NOACs, for those patients with atrial fibrillation. In particular, the WOEST, PIONEER and RE-DUAL-PCI studies will be considered.

Upon completion of this activity, participants will:

• Apply knowledge gained on the complex nature of antithrombotic therapies in non-valvular AF patients undergoing PCI in a range of clinical scenarios
• Increase knowledge on the complications surrounding triple antithrombotic therapy
• Understand the latest clinical evidence regarding the use of NOAC therapy in AF patients undergoing PCI